Patient’s ‘serious’ kidney injury halts gene therapy trial for Duchenne muscular dystrophy

The Food and Drug Administration has halted a clinical trial involving a Duchenne muscular dystrophy gene therapy from Solid Biosciences ...
gene editing

Why gene editing isn’t ready for treating human disease: It’s not ‘efficient enough’

Gene editing will likely always come with a bit of risk; when you're cutting and pasting DNA in millions of ...
Screen Shot at PM

Why ending muscle wasting matters for curing cancer

Deterioration of muscle is the cause of death in many diseases, like cancer, but no treatments address this lethal symptom ...
shea racing duchenne muscular dystrophy

Promising treatment for Duchenne muscular dystrophy developed with CRISPR gene editing

Duchenne muscular dystrophy is a life-threatening muscle-wasting illness. Occurring mostly in males, it is the most common type of muscular ...

CRISPR treatment for dogs with muscular dystrophy could one day lead to a cure for humans

Dogs suffering from muscular dystrophy are having their genomes edited with CRISPR, and the results are “mind-blowing.” Researchers from Texas ...

Duchenne muscular dystrophy gene therapy trial put on hold

Sarepta Therapeutics’ clinical trial for a gene therapy to treat Duchenne muscular dystrophy has been paused by the Food and ...
muscle jpg

Human muscles from stem cells: Advance could aid research into muscular dystrophy, other diseases

Muscle created with stem cells is not quite as strong as the researchers would like. But they think these new ...

Gene therapy 2.0: Will CRISPR make expensive treatment accessible to all?

Gene therapy, at a million dollars a treatment, will run up a patient's medical bill quickly. Can CRISPR-Cas9 gene editing ...
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists